Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Otsuka Partner Akebia Files HIF-PH Inhibitor Vadadustat in US
Otsuka Pharmaceutical and partner Akebia Therapeutics said on March 30 that a new drug application has been submitted in the US for their hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat. Cambridge, Massachusetts-based Akebia filed the drug with the FDA for…
To read the full story
Related Article
- Otsuka Ends Vadadustat Global License Deal with Akebia
May 16, 2022
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat Nixed in US
April 1, 2022
- Otsuka Files HIF-PH Inhibitor Vadadustat in Europe
November 1, 2021
- FDA Target Date for Vadadustat Set for March 29: Otsuka/Akebia
June 2, 2021
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
September 7, 2020
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
- Otsuka, Akebia Expand Licensing Pact for Anemia Med Vadadustat
April 27, 2017
- Otsuka, Akebia Form US Collaboration on Anemia Med Vadadustat
December 22, 2016
- Mitsubishi Tanabe Gains Exclusive Rights to Akebia’s Anemia Drug in Asia
December 16, 2015
BUSINESS
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…